Edwards Lifesciences wants a federal judge to invalidate a pair of patents covering nerve stimulation sensing technology owned by arch-rival Medtronic.
Edwards Lifesciences (NYSE:EW) wants a federal judge to rule that a pair of patents owned by arch-rival Medtronic (NYSE:MDT) are invalid because they aren’t specific enough.
The patents – the so-called ‘741 patent for a “Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure” and the ‘829 patent for a “Method and system for nerve stimulation prior to and during a medical procedure – cover nerve stimulation technology.
Edwards and Medtronic have spent considerable time in courts around the world, each arguing that the other’s transcatheter aortic valve implant infringes various patents.
